Merestinib on Bone Metastases in Subjects With Breast Cancer

Breast Cancer Clinical Trial

Official title:

An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects With Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03292536
• Other study ID #: HCI103657
• Status: Terminated
• Phase: Phase 1
• Start date: January 11, 2018
• Est. completion date: June 24, 2019

Study information

• Verified date: January 2021
• Source: University of Utah
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label, pharmacodynamics, intrapatient dose escalation phase 1B study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: June 24, 2019
• Est. primary completion date: June 24, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least 1 bone metastases must be present

• Urinary N-telopeptide level above 20nM BCE/mM creatinine measured at ARUP

• Archived or freshly biopsied primary and/or bone metastatic tumor tissue available in paraffin-embedded blocks or slides that is expected to yield 9 slides

• Life expectancy of = 6 months

• Toxicity related to prior treatments must either have resolved to grade 1 or less, returned to baseline, or be deemed irreversible

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (within 28 days prior to enrollment)

• Planning to remain on current breast cancer therapy for at least 12 weeks.

• At least one prior line of therapy for metastatic breast cancer

• Concurrent treatment with bisphosphonates or denosumab is required.

Exclusion Criteria:

• Unable to swallow or take anything orally

• ECG abnormalities:

• Prolonged QTcF (Fredericia's correction) interval on screening ECG (= 450 msec)

• QRS ? 120 msec

• PR ? 210 msec

• Any prior history, or current evidence of second- or third-degree heart block

• Heart rate ? 40 beats per minute at screening

• ECG second degree heart block (Mobitz's Type 2 or Wenckebach)

• Complete heart block

• Left bundle branch block or bifascicular block (right bundle branch block and left anterior hemiblock together)

• Episodes of ventricular tachycardia

• Any known prior malignancy (not including non-melanoma skin cancers), unless treated with curative intent

• A serious uncontrolled medical disorder or active infection, which would impair the ability of the subject to receive protocol therapy

• Current or recent (within 3 months) gastrointestinal disease that could impact the absorption (i.e., unmanageable diarrhea or malabsorption at the time of screening)

• Inadequate bone marrow function defined as:

• Absolute neutrophil count (ANC) ? 1,500 cells/mm3

• Platelet count ? 100,000 cells/mm3

• Hemoglobin ? 9 g/dL

• Inadequate hepatic function defined as:

• Total bilirubin ? 1.5 x institutional upper limit of normal (IULN) (Unless due to diagnosis of Gilbert's Syndrome)

• Alanine aminotransaminase (ALT) and aspartate aminotransaminase (AST) ? 2.5 x IULN

• Inadequate renal function defined as: Serum creatinine ? 1.5 x ULN

• Prothrombin time (PT)/partial thromboplastin time (PTT) ? 1.5 times the ULN

• Serum sodium, potassium, and calcium levels not within normal limits.

• Any atrophic macular condition including intermediate or advanced age-related macular degeneration

• Patients receiving medications that are known to be substrates of CYP2C8 (including paclitaxel), CYP2C9, or CYP2C19 or to be oral substrates of CYP3A with narrow therapeutic window (listed on http://medicine.iupui.edu/clinpharm/ddis/main-table). Subjects who have discontinued any of these medications must have a wash-out period of at least 5 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of merestinib

• Exposure to any investigational drug or placebo within 4 weeks of enrollment

• Any other sound medical, psychiatric, and/or social reasons as determined by the investigator

• History of diseases with influence on bone metabolism, such as Paget's disease, osteogenesis imperfecta, active primary or secondary hyperparathyroidism, and primary or secondary hyperthyroidism within 12 months prior to study entry

• Patients with known symptomatic brain metastasis. Subjects with controlled brain metastasis (no radiographic progression at least 4 weeks following radiation and/or surgical treatment and no neurological signs or symptoms) will be allowed

• History of allergy to merestinib or chemically related compounds

• History of osteonecrosis of the jaw

• Change in chemotherapy or hormone therapy within 8 weeks of the start of the study.

• Active gout or inflammatory arthritis requiring treatment

• Use within 28 days of registration of calcitonin, recombinant parathyroid hormone-related peptides, mithramycin, radium, strontium ranelate, or gallium nitrate.

• Adult patients who require monitored anesthesia for PET scanning due to claustrophobia.

Related Conditions & MeSH terms

• Bone Marrow Diseases
• Bone Metastases
• Bone Neoplasms
• Breast Cancer
• Breast Neoplasms
• Neoplasm Metastasis

Intervention

Drug:
• Merestinib
*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen* Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks

Locations

Country	Name	City	State
United States	Huntsman Cancer Institute	Salt Lake City	Utah

Sponsors (2)

Lead Sponsor	Collaborator
University of Utah	Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events that Occur	To assess the tolerability of merestinib in combination with standard breast cancer therapies.	12 weeks, checked at every visit in that time period
Primary	Change in urinary N-telopeptide level	To measure the change in urinary N-telopeptide level after 12 weeks of therapy with merestinib	12 weeks
Secondary	Absolute and percentage change in serum B-CTX, TRAP-5b, P1NP and BSAP	To measure the absolute and percentage change in serum ß-CTX, TRAP-5b, P1NP, and BSAP at time points from baseline to 12 weeks.	12 weeks
Secondary	Time to skeletal-related events	To evaluate determine time to skeletal-related event(s) following initiation of merestinib dosing	12 weeks
Secondary	Change in pain scores	To evaluate change in pain as measured by pain scores during and after 12 weeks of merestinib treatment	12 weeks
Secondary	Change in pain by narcotic use	To evaluate change in pain as measured by narcotic use) during and after 12 weeks of merestinib treatment	12 weeks
Secondary	Change in bone lesion uptake	To evaluate the change in bone lesion uptake on NaF PET scan after 12 weeks of merestinib treatment	12 weeks